IS IT POSSIBLE TO USE BEVACIZUMAB BIOSIMILAR IN ALL INDICATIONS REGISTERED FOR ORIGINAL DRUG?

IS IT POSSIBLE TO USE BEVACIZUMAB BIOSIMILAR IN ALL INDICATIONS REGISTERED FOR ORIGINAL DRUG?

The possibility of extrapolation of indications for biosimilars is one of the issues widely discussed in modern literature. Currently, the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) have identified specific conditions under which for biosimilars extrapolation of indic...

Full description

Bibliographic Details
Main Authors:	S. V. Orlov, N. L. Shimanovskii, S. N. Fogt
Format:	Article
Language:	Russian
Published:	QUASAR, LLC 2016-06-01
Series:	Issledovaniâ i Praktika v Medicine
Subjects:	bevacizumab safety biosimilar bcd-021 non-small cell lung carcinoma extrapolation of indications efficacy
Online Access:	https://www.rpmj.ru/rpmj/article/view/137

Similar Items

Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial
by: Т. V. Korotaeva, et al.
Published: (2018-12-01)

Pharmacoeconomic aspects of biosimilars
by: A A Tryakin, et al.
Published: (2017-01-01)

Authorisation of Non-Innovator Biotherapeutic (Biosimilar) Products in the USA
by: A. A. Soldatov, et al.
Published: (2019-03-01)

Comparative efficacy and safety of infliximab biosimilar (BCD-055) and innovator infliximab in patients with ankylosing spondylitis (results of international, multiple-center, double-blind phase I and phase III clinical studies)
by: D. E. Karateev, et al.
Published: (2017-09-01)

COMPARATIVE EVALUATION OF THE LONG-TERM EFFICACY AND SAFETY OF THE INFLIXIMAB BIOSIMILAR BCD-055 AND REFERENCE INFLIXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF THE INTERNATIONAL MULTICENTER RANDOMIZED DOUBLE-BLIND PHASE III CLINICAL STUDY ASART-2
by: A. M. Lila, et al.
Published: (2018-07-01)

Biosimilars and the extrapolation of indications for inflammatory conditions
by: Tesser JRP, et al.
Published: (2017-02-01)

Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey
by: Monk, Bradley, et al.
Published: (2017)

Validation of a Size-Exclusion Chromatography Method for Bevacizumab Quantitation in Pharmaceutical Preparations: Application in a Biosimilar Study
by: Alexis Oliva, et al.
Published: (2019-09-01)

Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial
by: Yuankai Shi, et al.
Published: (2021-09-01)

Toxicity and efficacy of biosimilar bevacizumab in the second-line therapy for metastatic colon cancer in routine clinical practice: results of an independent observational study
by: M. Yu. Fedyanin, et al.
Published: (2021-06-01)

Clinical and Regulatory Concerns of Biosimilars: A Review of Literature
by: Vesa Halimi, et al.
Published: (2020-08-01)

A Randomized, Double-Blind, Single-Dose Study Comparing the Biosimilarity of HOT-1010 With Bevacizumab (Avastin®) in Chinese Healthy Male Subjects
by: Kai Huang, et al.
Published: (2021-06-01)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
by: Zhou X, et al.
Published: (2021-07-01)

Safety of Intravitreal Injection of Stivant, a Biosimilar to Bevacizumab, in Rabbit Eyes
by: Alireza Lashay, et al.
Published: (2020-08-01)

The biosimilars journey: current status and ongoing challenges
by: Igor Age Kos, et al.
Published: (2018-10-01)

Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial
by: Tianqing Chu, et al.
Published: (2021-08-01)

Pharmacovigilance of biosimilars – Why is it different from generics and innovator biologics?
by: B Oza, et al.
Published: (2019-01-01)

Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey
by: Jay U Sheth, et al.
Published: (2021-01-01)

A Comparative Parallel Study of Pharmacokinetics and Immunogenicity Following Single Intravenous Administration of Bevacizumab Biosimilar RPH-001 (Manufactured by R-Pharm Group, Russia) and Avastin® (Manufactured by F. Hoffmann-La Roche Ltd., Switzerland) in Healthy Male Volunteers
by: M. A. Kolganova, et al.
Published: (2019-09-01)

Are We Ready for Biosimilars in Gastroenterology?
by: Muhammad Ilham Abdul Hafidz, et al.
Published: (2017-12-01)

Acceptable Safety of Bevacizumab Therapy in Combination with Chemotherapy in Patients with Advanced Lung Cancer
by: Wei WU, et al.
Published: (2009-03-01)

SAFETY AND CLINICAL EFFICACY IN BIOSIMILAR SUBSTITUTION
by: João Pedro Fernandes, et al.
Published: (2015-01-01)

Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
by: XiaoQin Lu, et al.
Published: (2021-04-01)

The safety of biological preparations. Part 2. Safety issues of biosimilars
by: A. A. Soldatov, et al.
Published: (2018-02-01)

Bevacizumab for non-small cell lung cancer patients with brain metastasis: A meta-analysis
by: Liang Ping, et al.
Published: (2020-07-01)

Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?
by: Victor M. Rivera
Published: (2019-07-01)

A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
by: Yuankai Shi, et al.
Published: (2020-04-01)

Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia
by: Sevinç A, et al.
Published: (2018-01-01)

Biosimilars in rheumatology and other fields of medicine
by: Marcin Milchert, et al.
Published: (2014-07-01)

New Quality-Range-Setting Method Based on Between- and Within-Batch Variability for Biosimilarity Assessment
by: Alexis Oliva, et al.
Published: (2021-06-01)

Biosimilars and Switching: What Is Your Perspective?
by: Sandoz
Published: (2017-08-01)

On the Regulatory Approval Pathway of Biosimilar Products
by: Jun Wang, et al.
Published: (2012-03-01)

Libraries and society in Shanghai 1840-1949
by: Wu, Jianzhong
Published: (1991)

Safety of Neoadjuvant Bevacizumab plus Pemetrexed and Carboplatin  in Patients with IIIa Lung Adenocarcinoma
by: Songliang ZHANG, et al.
Published: (2015-06-01)

Biosimilars: presumption of guilt
by: Marina Vladimirovna Shestakova, et al.
Published: (2011-12-01)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
by: Ioana Gherghescu, et al.
Published: (2021-12-01)

Efficacy and Safety of Bevacizumab Combined with Chemotherapy as Second-line or Later-line Treatment in Advanced Nonsquamous Non-small Cell Lung Cancer
by: Xuanxuan ZHENG, et al.
Published: (2018-07-01)

Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review
by: Arnold G. Vulto, et al.
Published: (2020-11-01)

SUCCESSFUL REGISTRATION OF DOMESTIC BIOANALOGUE OF BEVACIZUMAB – NEW OPPORTUNITIES FOR EFFECTIVE TREA TMENT OF PATIENTS WITH NON-SQUAMOUS CELL NON-SMALL CELL LUNG CANCER
by: S. V. Orlov, et al.
Published: (2016-01-01)

Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab
by: Muñoz-Villegas P, et al.
Published: (2021-05-01)